Skip to main content

Cinobac Side Effects

Generic name: cinoxacin

Medically reviewed by Drugs.com. Last updated on Jan 26, 2024.

Note: This document contains side effect information about cinoxacin. Some dosage forms listed on this page may not apply to the brand name Cinobac.

Applies to cinoxacin: oral capsule.

General

Cinoxacin (the active ingredient contained in Cinobac) is generally well tolerated. Adverse effects occur in approximately 5% of treated patients.[Ref]

Gastrointestinal

Cinoxacin (the active ingredient contained in Cinobac) most commonly affects the gastrointestinal system, causing nausea, vomiting, and diarrhea in approximately 3% of treated patients.[Ref]

Nervous system

Nervous system toxicity occurs in approximately 2% of patients treated with cinoxacin (the active ingredient contained in Cinobac) and may include headache, dizziness, nervousness, and insomnia. Rarely, blurred vision has been reported. Other adverse effects rarely include paresthesias, somnolence, photophobia, and tinnitus.[Ref]

Hypersensitivity

Hypersensitivity reactions have been reported following cinoxacin (the active ingredient contained in Cinobac) administration in approximately 3% of patients. Hypersensitivity reactions most commonly involve rash, urticaria, pruritus, and edema. Anaphylaxis has been reported in a few patients who were previously sensitized to cinoxacin. A case of Henoch-Schonlein purpura has also been reported.[Ref]

Hepatic

Hepatic effects of cinoxacin (the active ingredient contained in Cinobac) have rarely included transient elevations of liver function tests.[Ref]

References

1. Cinoxacin (Cinobac)--a new drug for urinary tract infections. Med Lett Drugs Ther. 1981;23:57-8.

2. Sisca TS, Heel RC, Romankiewicz JA. Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections. Drugs. 1983;25:544-69.

3. Scavone JM, Gleckman RA, Fraser DG. Cinoxacin: mechanism of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy. 1982;2:266-72.

4. Stamey TA. Cinoxacin: an overview. Urology. 1981;17:492-5.

5. Sabbour MS, El Bokl MA, Osman LM. Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI). Infection. 1984;12:377-80.

6. Burt RA. Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections. Urology. 1984;23:101-7.

7. Goldstein EJ, Kahn RM, Alpert ML, Ginsberg BP, Greenway FL, Citron DM. Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. Am J Med. 1987;82:284-7.

8. Schaeffer AJ, Flynn S, Jones J. Comparison of cinoxacin and trimethoprim-sulfamethoxazole in the treatment of urinary tract infections. J Urol. 1981;125:825-7.

9. Cox CE, Simmons JR. Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy. South Med J. 1982;75:549-50.

10. Cox CE, Simmons JR. Cinoxacin in therapy of urinary tract infections. Comparison of two dosage regimens. Urology. 1981;17:539-41.

11. Stricker BH, Slagboom G, Demaeseneer R, Slootmaekers V, Thijs I, Olsson S. Anaphylactic reactions to cinoxacin. BMJ. 1988;297:1434-5.

12. Drago F, Arditi MR, Rebora A. Henoch-schonlein purpura induced by fluoroquinolones. Br J Dermatol. 1994;131:448.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer